Human Reproduction · 2009 · 327 citations · 107 references
MedicineEndocrinologyGynecologyReproductive EndocrinologyReproductive MedicineReproductive PhysiologyDiminished Ovarian ReserveFollicular DynamicsOvarian FunctionOvarian PhysiologyOvarian ReservePolycystic Ovary SyndromeAnti-müllerian Hormone AssessmentBiomarkers Of Ovarian FunctionOvarian Follicle PhysiologyOvarian Follicle PoolOvarian Function AssessmentOvarian Function TestingOvarian Reserve DepletionPremature Ovarian Failure
Anti‑Müllerian hormone is produced by granulosa cells of early follicles, inhibits the primordial‑to‑primary transition, and its serum level reflects the number of small antral follicles, declining with age and becoming undetectable after menopause, being low in premature ovarian failure, elevated in PCOS, and thus serving as a marker of ovarian reserve. The study aims to evaluate AMH measurement as a predictor of poor and hyper‑ovarian response to gonadotrophin stimulation in IVF and to identify key unanswered questions regarding its physiology and clinical use.
In the ovary, Anti-Müllerian hormone (AMH) is produced by the granulosa cells of early developing follicles and inhibits the transition from the primordial to the primary follicular stage. AMH levels can be measured in serum and have been shown to be proportional to the number of small antral follicles. In women serum AMH levels decrease with age and are undetectable in the post-menopausal period. In patients with premature ovarian failure AMH is undetectable or greatly reduced depending of the number of antral follicles in the ovaries. In contrast, AMH levels have been shown to be increased in women with polycystic ovary syndrome (PCOS). AMH levels appear to represent the quantity of the ovarian follicle pool and may become a useful marker of ovarian reserve. AMH measurement could also be useful in the prediction of the extremes of ovarian response to gonadotrophin stimulation for in vitro fertilization, namely poor- and hyper-response. Although AMH has the potential to increase our understanding of ovarian pathophysiology, and to guide clinical management in a broad range of conditions, a number of important questions relating to both the basic physiology of AMH and its clinical implications need to be answered.
107
Horder, William Harnett · BMJ · 1941 · 1.3K citations · Full text
Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve
Ilse A.J. van Rooij · Human Reproduction · 2002 · 950 citations · Full text
Medicine, Endocrinology, Gynecology +17
Antimüllerian hormone serum levels: a putative marker for ovarian aging
Annemarie de Vet, Joop S.E. Laven, Frank H. de Jong et al. · Fertility and Sterility · 2002 · 886 citations · Full text
Medicine, Endocrinology, Gynecology +14